Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin

Bone

Volumn 45, Issue 4, 2009, Pages 669-676

  Li, Xiaodong ^a   Ominsky, Michael S ^a   Stolina, Marina ^a   Warmington, Kelly S ^a   Geng, Zhaopo ^a   Niu, Qing Tian ^a   Asuncion, Frank J ^a   Tan, Hong Lin ^a   Grisanti, Mario ^a   Dwyer, Denise ^a   Adamu, Steven ^a   Ke, Hua Zhu ^a   Simonet, W Scott ^a   Kostenuik, Paul J ^a  

^a AMGEN INC   (United States)

Author keywords

Androgen ablation; Micro CT; OPG; Orchiectomy; RANKL

Indexed keywords

HUMAN OSTEOPROTEGERIN FC; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MARROW; BONE MASS; CELL SURFACE; CONTROLLED STUDY; CORTICAL BONE; DENSITOMETRY; LUMBAR VERTEBRA; MALE; MORPHOMETRICS; NONHUMAN; ORCHIECTOMY; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RAT; TESTOSTERONE BLOOD LEVEL; TRABECULAR BONE;

ACID PHOSPHATASE; ANIMALS; BONE DENSITY; BONE MARROW; BONE RESORPTION; FEMUR NECK; HUMANS; ISOENZYMES; LUMBAR VERTEBRAE; MALE; ORCHIECTOMY; OSTEOPROTEGERIN; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; X-RAY MICROTOMOGRAPHY;

EID: 68849132198     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.06.011     Document Type: Article

References (57)

1. Greenspan S.L., Coates P., Sereika S.M., Nelson J.B., Trump D.L., and Resnick N.M. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J. Clin. Endorinol. Metab. 90 (2005) 6410-6417
2. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352 (2005) 154-164
3. Benito M., Gomberg B., Wehrli F.W., Weening R.H., Zemel B., Wright A.C., et al. Deterioration of trabecular architecture in hypogonadal men. J. Clin. Endorinol. Metab. 88 (2003) 1497-1502
4. Turner R.T., Hannon K.S., Demers L.M., Buchanan J., and Bell N.H. Differential effects of gonadal function on bone histomorphometry in male and female rats. J. Bone Miner. Res. 4 (1989) 557-563
5. Turner R.T., Wakley G.K., and Hannon K.S. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J. Orthop. Res. 8 (1990) 612-617
6. Erben R.G., Eberle J., Stahr K., and Goldberg M. Androgen deficiency induced high turnover osteopenia in aged male rats: a sequential histomorphometric study. J. Bone Miner. Res. 15 (2000) 1085-1098
7. Audran M., Chappard C., Legrand E., Libouban H., and Basle M.F. Bone microarchitecture and bone fragility in men: DXA and histomorphometry in humans and in the orchidectomized rat model. Calcif. Tissue Int. 69 (2001) 214-217
8. Gunness M., and Orwoll E. Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats. J. Bone Miner. Res. 10 (1995) 1735-1744
9. Erben R.G., Brunner K.S., Breig B., Eberle J., Goldberg M., and Hofbauer L.C. Skeletal effects of cyclosporin A are gender related in rats. Endocrinology 144 (2003) 40-49
10. Vandenput L., Boonen S., van Herck E., Swinnen J.V., Bouillon R., and Vanderschueren D. Evidence from the aged orchidectomized male rat model that 17b-estradiol is a more effective bone-sparing and anabolic agent than 5a-dihydroxytestosterone. J. Bone Miner. Res. 17 (2002) 2080-2086
11. Vanderschueren D., Vandenput L., Boonen S., van Herck E., Swinnen J.V., and Bouillon R. An aged rat model of partial androgen deficiency: prevention of both loss of bone and lean body mass by low-dose androgen replacement. Endocrinology 141 (2000) 1642-1647
12. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
13. Simonet W.S., Lacey D.L., Dunstan C., Kelly M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
14. Burgess T., Qian Y.X., Kaufman S., Ring B.D., Van G., Capparelli C., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145 (1999) 527-538
15. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G., Qiu W., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157 (2000) 435-448
16. Grimaud E., Soubigou L., Couillaud S., Coipeau P., Moreau A., Passuti N., et al. Receptor activator of nuclear factor kB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol. 163 (2003) 2021-2031
17. Huber D.M., Bendixen A.C., Pathrose P., Srivastava S., Dienger K.M., Shevde N.K., et al. Androgens suppress osteoclast formation induced by RANKL and macrophage colony-stimulating factor. Endocrinology 142 (2001) 3800-3808
18. Michael H., and Harkonen P.L. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J. Bone Miner. Res. 20 (2005) 2224-2232
19. Udagawa N., Takahashi N., Jimi E., Matsuzaki K., Tsurakai T., Itoh K., et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor. Bone 25 (1999) 517-523
20. Udagawa N., Takahashi N., Yasuda H., Mizuno A., Itoh K., Ueno Y., et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141 (2000) 3478-3484
21. Chen Q., Kaji H., Kanatani M., Sugimoto T., and Chihara K. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm. Metab. Res. 36 (2004) 674-678
22. Kawano H., Sato T., Yamada T., Matsumoto T., Sekine K., Watanabe T., et al. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9416-9421
23. Franklin M., Bu S.Y., Lerner M.R., Lancaster E.A., Bellmer D., Marlow D., et al. Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. Bone 39 (2006) 1331-1342
24. Kim B.T., Mosekilde L., Duan Y., Zhang X.Z., Tornvig L., Thomsen J.S., et al. The structural and hormonal basis of sex differences in peak appendicular bone strength in rats. J. Bone. Miner. Res. 18 (2003) 150-155
25. Prakasam G., Yeh J.K., Chen M.M., Castro-Magana M., Liang C.T., and Alioa J.F. Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats. Bone 24 (1999) 491-497
26. Alatalo S.L., Peng Z., Janckila A.J., Kaija H., Vihko P., Vaananen H.K., et al. A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. J. Bone Miner. Res. 18 (2003) 134-139
27. Vanderschueren D., van Herck E., Nijs J., Ederveen A., De Coster R., and Bouillon R. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology 138 (1997) 2301-2307
28. Samadfam R., Xia Q., and Goltzman D. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J. Bone Miner. Res. 22 (2007) 55-63
29. Ominsky M.S., Li X., Asuncion F., Barrero M., Warmington K., Dwyer D., et al. RANKL inhibition with osteoprotegerin (OPG) increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J. Bone Miner. Res. 23 (2008) 672-682
30. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J. Bone Miner. Res. 2 (1987) 595-610
31. Qiu S., Rao D.S., Palnitkar S., and Parfitt A.M. Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone. Bone 31 (2002) 313-318
32. Szulc P., Claustrat B., Marchand F., and Delmas P.D. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J. Clin. Endorinol. Metab. 88 (2003) 5240-5247
33. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 397 (1999) 315-323
34. Clohisy D.R., Ramnaraine M.L., Scully S., Qi M., Van G., Tan H.L., et al. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J. Orthop. Res. 18 (2000) 967-976
35. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159 (2001) 1689-1699
36. Stolina M., Adamu S., Ominsky M.S., Dzamba B.J., Asuncion F., Geng Z., et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J. Bone. Miner. Res. 20 (2005) 1756-1765
37. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., and Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111 (2003) 1221-1230
38. Cao J., Venton L., Sakata T., and Halloran B.P. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J. Bone Miner. Res. 18 (2003) 270-277
39. Hofbauer L.C., Hicok K.C., Chen D., and Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur. J. Endocrinol. 147 (2002) 269-273
40. Gruber R., Czerwenka K., Wolf F., Ho G.M., Willheim M., and Peterlik M. Expression of the vitamin D receptor, of estrogen and thyroid hormone receptor a- and b-isoforms, and of the androgen receptor in cultures of native mouse bone marrow and of stromal/osteoblastic cells. Bone 24 (1999) 465-473
41. Mantalaris A., Panoskaltsis N., Sakai Y., Bourne P., Chang C., Messing E.M., et al. Localization of androgen receptor expression in human bone marrow. J. Pathol. 193 (2001) 361-366
42. Abu E.O., Horner A., Kusec V., Triffitt J.T., and Compston J.E. The localization of androgen receptors in human bone. J. Clin. Endocrinol. Metab. 82 (1997) 3493-3497
43. Venken K., DeGendt K.D., Boonen S., Ophoff J., Bouillon R., Swinnen J.V., et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J. Bone. Miner. Res. 21 (2006) 576-585
44. Taxel P., Kaneko H., Lee S.K., Aguila H.L., Raisz L.G., and Lorenzo J.A. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos. Int. 19 (2008) 193-199
45. Ikeda T., Kasai M., Utsuyama M., and Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kB ligand and their differential expression in bone and thymus. Endocrinology 142 (2001) 1419-1426
46. Findlay D, Chehade M, Tsangari H, Neale S, Hay S, Hopwood B, et al. Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. 2008;10(1):R2.
47. Benito M., Vasilic B., Wehrli F.W., Bunker B., Wald M., Gomberg B., et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J. Bone Miner. Res. 20 (2005) 1785-1791
48. Nakamura M., Udagawa N., Matsuura S., Mogi M., Nakamura H., Horiuchi H., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144 (2003) 5441-5449
49. Reim N.S., Brieg B., Stahr K., Eberle J., Hoeflich A., Wolf E., et al. Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling. J. Bone Miner. Res. 23 (2008) 694-704
50. Capparelli C., Morony S., Warmington K., Adamu S., Lacey D., Dunstan C.R., et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J. Bone Miner. Res. 18 (2003) 852-858
51. Zhou H., Iida-Klein A., Lu S.S., Ducayen-Knowles M., Levine L.R., Dempster D.W., et al. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32 (2003) 513-520
52. Kasperk C.H., Wakley G.K., Hierl T., and Ziegler R. Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J. Bone Miner. Res. 12 (1997) 464-471
53. Fan W., Crawford R., and Xiao Y. Structural and cellular differences between metaphyseal and diaphyseal periosteum in different aged rats. Bone 42 (2008) 81-89
54. Ross A.B., Bateman T.A., Kostenuik P.J., Ferguson V.L., Lacey D.L., Dunstan C.R., et al. The effects of osteoprotegerin on the mechanical properties of rat bone. J. Mater. Sci. Mater. Med. 12 (2001) 583-588
55. Ke H.Z., Crawford D.T., Qi H., Chidsey-Frink K.L., Simmons H.A., Li M., et al. Long-term effects of aging and orchidectomy on bone and body composition in rapidly growing male rats. J. Musculoskel. Neuron. Interact. 1 (2001) 215-224
56. Review. Rogers A., and Eastell R. Circulating osteoprotegerin ligand and receptor activator for nuclear factor kB ligand: clinical utility in metabolic bone disease assessment. J. Clin. Endorinol. Metab. 90 (2005) 6323-6331
57. Kostenuik P.J. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr. Opin. Pharmacol. 5 (2005) 618-625